The FLT3 inhibitor Quizartinib may benefit FLT3 wild-type AML patients who exhibit a specific gene expression profile indicating "FLT3 addiction." This is based on the rationale that FLT3 is overexpressed on all AML blasts, not just mutated ones, potentially doubling the drug's eligible patient population.

The ASXL1 mutation, found in 11-15% of newly diagnosed CML patients, negates the efficacy benefit of the highly specific BCR-ABL inhibitor Asciminib. This suggests that for this patient subset, Asciminib monotherapy is insufficient, and combination treatments are likely necessary to overcome this form of molecular resistance.

While the new CML drug Asciminib demonstrates better efficacy, its most significant advantage is superior tolerability. Clinical trial data shows it causes significantly fewer treatment discontinuations due to adverse events compared to both Imatinib and second-generation TKIs, improving patient adherence and quality of life.

While pan-RAS inhibitors like daroxiracib can target multiple mutations, they cause significantly more GI and skin toxicity. For a homogenous KRAS G12C mutation, a mutant-selective inhibitor is preferred as it offers comparable efficacy with a much more manageable side effect profile, crucial for maintaining dose intensity.

The IDH1 inhibitor olutasidenib demonstrates a much longer duration of response than ivosidenib. One hypothesis is that olutasidenib's weaker affinity for wild-type IDH1 makes it a more selective inhibitor of the mutant protein, leading to more durable disease control.

Pirtobrutinib's reduced side effects, like atrial fibrillation, stem from its precise targeting of BTK with minimal 'binding promiscuity' to other kinases. This makes it a safer option for patients who have already been on a less-targeted BTK inhibitor.

The pan-RAF inhibitor tovorafenib causes a significant, but reversible, decrease in growth velocity in children. This is not due to endocrinopathy but direct C-RAF inhibition slowing growth plate maturation. Growth resumes and "catches up" after therapy cessation, a critical counseling point for families.

Unlike lenalidomide, which modulates CK1-alpha and can select for p53-mutated cells leading to a risk of secondary leukemia/MDS, both iberdomide and mezigdemide do not share this off-target effect. This critical safety difference makes them promising candidates for long-term use, such as in maintenance therapy.

Risk stratification in CML is moving beyond BCR-ABL. Additional mutations like ASXL1 are now known to predict poorer outcomes and reduced response to asciminib, while others like GATA2 are favorable, pushing for routine, broader genetic sequencing at diagnosis to personalize therapy.